EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma

Ida Steiro, Synne Stokke Tryggestad, Eli Svorkdal Hess, Hanne Hella, Pegah Abdollahi, Kari Lenita Falck Moore, Margrete Friestad, Magne Børset, Tobias S. Slørdahl, Anne Marit Sponaas

eJHaem · 2026-10 · 7 (5)

DOI: 10.1002/jha2.70388 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients. Methods We used ELISpot and flow cytometry to test the T cell response to BCMA‐CD3‐bispecific T cell engager (BiTE) pavurutamab (PAV) and BCMA‐expressing myeloma cells after in vitro culture. Results Reduced pathogen‐specific responses were found in T cells cultured with PAV yet they killed myeloma cells. In an exploratory study, reduced pathogen‐specific memory T cell responses were detected in PBMCs from four myeloma patients responding to BCMA‐targeted BsAb therapy. Conclusion Our preliminary observation and its link to infection should be followed up in a larger study. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →